ArticleCase reports in dermatology
Dermatofibrosarcoma Protuberans at the Presumed Injection Site following CoronaVac COVID-19 Vaccination: A Case Report.
Article in Case reports in dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Dermatofibrosarcoma protuberans (DFSP) is a rare, slow-growing, locally aggressive cutaneous sarcoma. Trauma and scars have been proposed as potential triggers in a subset of cases. Case Presentation: We report a 30-year-old man who developed a progressively enlarging mass in the left deltoid region within several months after receiving two doses of the CoronaVac COVID-19 vaccine administered to the same arm. The lesion was diagnosed as DFSP approximately 19 months after vaccination. Histopathology showed a storiform spindle-cell neoplasm with diffuse CD34 positivity, and fluorescence in situ hybridization demonstrated the COL1A1-PDGFB fusion, consistent with DFSP. The tumor was managed with wide local excision with 2-cm clinical margins; final margins were negative. At 24 months of follow-up after surgery, there was no evidence of local recurrence or metastasis. Conclusions: This case illustrates a temporal association between a new mass at a presumed injection site and DFSP. While causality cannot be inferred from a single case, persistent post-injection nodules should prompt evaluation. The overall benefits of COVID-19 vaccination remain substantial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.